NCT00418093: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
|
|
| Terminated | 2 | 19 | US | Gemcitabine, Oxaliplatin, Bevacizumab | Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Eli Lilly and Company, Sanofi-Synthelabo, Genentech, Inc. | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 01/11 | 10/11 | | |
NCT01936974: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma |
|
|
| Terminated | 2 | 7 | US | Gemcitabine, Gemzar, Bevacizumab, Avastin, Carboplatin, Paraplatin, Cisplatin, Platinol, Oxaliplatin, Eloxatin | Western Regional Medical Center | Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma | 08/15 | 08/15 | | |
